Keyphrases
Clinical Trials
14%
Confidence Interval
85%
Control Subjects
14%
COVID-19 Infection
14%
COVID-19 Vaccine
14%
Disease Flare
14%
First Dose
14%
Humoral Immune Response
14%
Immunogenicity
100%
Interleukin-17 (IL-17)
14%
Low Dose Rate
14%
MEDLINE
14%
Meta-analysis
100%
Mycophenolate
28%
Odds Ratio
14%
PubMed
14%
Rheumatic Diseases
100%
Rituximab
28%
SARS-CoV-2 Vaccination
100%
SARS-CoV-2 Vaccine
14%
Scopus
14%
Second Dose
14%
Seroconversion
57%
Seroconversion Rate
14%
Serological Response
14%
Severe Adverse Events
14%
Systematic Meta-analysis
100%
Tumour Necrosis Factor Inhibitor (TNFi)
14%
Vaccination
14%
Vaccination against SARS-CoV-2
14%
Vaccine Response
14%
Vaccine Types
14%
Medicine and Dentistry
Adverse Event
14%
Clinical Trial
14%
COVID-19
14%
COVID-19 Vaccination
100%
COVID-19 Vaccine
28%
Disease
14%
Disease Exacerbation
14%
Humoral Immunity
14%
Immunogenicity
100%
Immunosuppressant
14%
Immunosuppressive Drug
14%
Infection
14%
Interleukin 17
14%
Meta-Analysis
100%
Mycophenolic Acid
28%
Observational Study
14%
Odds Ratio
14%
Rheumatic Disease
100%
Rituximab
28%
Seroconversion
71%
Severe Acute Respiratory Syndrome Coronavirus 2
14%
Systematic Review
100%
TNF Inhibitor
14%
Immunology and Microbiology
COVID-19
28%
Humoral Immunity
14%
Immunogenicity
100%
Immunosuppressant
14%
Immunosuppressive Drug
14%
Interleukin 17
14%
Medline
14%
Mycophenolic Acid
28%
Rheumatic Disease
100%
Rituximab
28%
Scopus
14%
Seroconversion
71%
Severe Acute Respiratory Syndrome Coronavirus 2
100%
TNF Inhibitor
14%
Pharmacology, Toxicology and Pharmaceutical Science
Adverse Event
14%
Clinical Trial
14%
COVID-19 Vaccine
28%
Disease
14%
Disease Exacerbation
14%
Immunogenicity
100%
Immunosuppressive Agent
28%
Infection
14%
Interleukin 17
14%
Mycophenolic Acid
28%
Observational Study
14%
Rheumatic Disease
100%
Rituximab
28%
SARS Coronavirus
100%
Tumor Necrosis Factor Inhibitor
14%